
Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) – HC Wainwright raised their FY2026 earnings estimates for shares of Alto Neuroscience in a research note issued on Thursday, November 12th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($2.50) per share for the year, up from their previous forecast of ($2.82). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q4 2026 earnings at ($0.57) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.70) EPS, Q4 2027 earnings at ($0.69) EPS, FY2027 earnings at ($2.70) EPS, FY2028 earnings at ($3.39) EPS, FY2029 earnings at ($3.46) EPS and FY2030 earnings at ($3.02) EPS.
A number of other research analysts also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Tuesday, October 27th. Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. BTIG Research restated a “buy” rating and set a $37.00 target price on shares of Alto Neuroscience in a research report on Wednesday, November 11th. Finally, Wedbush lifted their price target on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus price target of $37.88.
Get Our Latest Analysis on ANRO
Alto Neuroscience Stock Down 8.3%
ANRO stock opened at $24.87 on Monday. The firm has a market cap of $997.66 million, a PE ratio of -10.19 and a beta of 1.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.12 and a current ratio of 18.12. The firm’s fifty day moving average is $25.99 and its 200 day moving average is $24.74. Alto Neuroscience has a one year low of $12.51 and a one year high of $37.48.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.13.
Insider Activity
In other news, CFO Nicholas Smith sold 110,830 shares of the stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the transaction, the chief financial officer owned 24,060 shares in the company, valued at $639,514.80. This trade represents a 82.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 11.25% of the stock is owned by company insiders.
Institutional Investors Weigh In On Alto Neuroscience
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in shares of Alto Neuroscience by 70.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 404,674 shares of the company’s stock worth $10,331,000 after purchasing an additional 167,844 shares during the last quarter. Bellevue Group AG purchased a new position in Alto Neuroscience in the 3rd quarter valued at about $29,706,000. Marshall Wace LLP lifted its stake in Alto Neuroscience by 281.1% in the 3rd quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock valued at $21,938,000 after buying an additional 633,806 shares in the last quarter. Empowered Funds LLC purchased a new position in Alto Neuroscience in the 3rd quarter valued at about $299,000. Finally, HighVista Strategies LLC acquired a new stake in Alto Neuroscience in the 3rd quarter worth about $922,000.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
